Why this is worth thinking about now
JCA only began in 2025, with oncology and ATMP products first in scope. Orphan medicines follow in 2028. Most rare disease teams are not yet working through JCA directly – but many are watching the early oncology assessments carefully and asking what they will need to have in place when their programmes reach that point.
What those early assessments have shown is that JCA is not simply a more complex version of national HTA. It surfaces differences in how evidence is interpreted across multiple Member States simultaneously – and the organisations best placed to navigate that are those who have prepared their internal thinking well in advance.
Based on what the early assessments have revealed, and on conversations with teams across the industry, some consistent themes are emerging in how organisations are starting to think about this:
- How do you ensure JCA thinking is visible at the moments when key asset decisions are being shaped?
- How do EU perspectives reach global decision-makers early enough to influence decisions – particularly where those decisions sit outside EU functions?
- Who owns JCA thinking at asset level – and how is that made clear across functions?
- How do you apply JCA thinking upstream, rather than as a layer added on top of existing HTA processes?
- How do you approach areas such as patient input and COI in a JCA context, where expectations are still forming?
These are not simple questions – and the answers will look different for every organisation and every asset. But the teams that start building their internal architecture now will be significantly better placed than those who wait until JCA timelines are already in motion.
What RAREready provides
We work with cross-functional rare disease teams to make JCA thinking visible, owned and usable – before it becomes urgent.
Asset-level working sessions Structured conversations with your US and EU colleagues, focused on real decisions on live assets. We work to establish what changes when those decisions are viewed through a JCA lens, what may be worth doing differently now, and where ownership of JCA thinking could be made clearer across functions.
Interpretation and evidence review We review your existing evidence, outcomes and patient insight through a JCA lens – giving teams a clear view of what their current work already supports, and where it may be worth building further clarity before assessment timelines begin.
Cross-functional alignment We bring Medical, Access, Evidence, Clinical and Patient Engagement teams to a shared upstream view – supporting consistent internal understanding of what JCA is likely to require and when, across functions and geographies.
Affiliate and global coordination We give affiliates clear, realistic guidance on what to watch for and how to contribute early – without drifting into HTA territory or creating additional burden on local teams.
Decision tools and playbooks Where useful, we develop concise, asset-specific resources that teams can use at the moments that matter – making explicit what questions are worth asking, what good looks like, and who is best placed to act.
Who RAREready™ supports
- Rare disease and ATMP programme leads
- EU and Global Market Access and Policy
- Medical Affairs
- Patient Engagement & Advocacy
- Evidence and Clinical teams
- Affiliates
- US biotechs preparing for Europe
If JCA is starting to surface in internal conversations – and you are looking for a practical, low-key way to think it through RAREready is built for you.
What we do not do
RAREready is delivered by swii.ch health – a specialist consultancy combining rare disease patient insight, behavioural science and digital expertise.
That combination matters. Preparing an organisation to act consistently on new requirements – across functions, geographies and asset lifecycles – requires more than knowledge transfer. It requires understanding how decisions are made in practice, how to connect new ways of thinking to established workflows, and how patient insight can be structured in ways that will hold up under joint assessment scrutiny.
Most JCA support focuses on evidence strategy. We work earlier, and differently – on the decisions and internal conditions that determine whether that evidence work lands as intended.
We work as a focused, senior team. The people you speak to at the outset are the people who deliver.
A 20-minute call is often enough to understand what is most relevant and where to start.
From Our Expert Blog at swii.ch
Insights from the team behind RAREready
EU Joint Clinical Assessment (JCA) in Rare Disease
Where synchronised EU scrutiny changes internal exposure and governance design → Read on swii.ch
EU JCA is Underway
A shared EU evaluation of evidence has begun. See what it means for rare-disease sponsors and why patient evidence will define future success. → Read on swii.ch
EU JCA Readiness: Why 2026 Changes Planning
What early implementation signals reveal about PICO decisions and upstream ownership → Read on swii.ch
5 Patient Evidence Myths That Undermine EU JCA Strategy
Common structural misunderstandings that weaken comparative positioning → Read on swii.ch
EU JCA 2025 Explained
Oncology in 2025. Orphan medicines from 2028. Why early evidence design now determines flexibility later → Read on swii.ch
Europe’s Shift to Patient Evidence
What the first JCAs tell us about how patient evidence will be viewed in rare-disease assessments. → Read more on Swii.ch Health
Next Steps
A 20-minute call is often enough to understand your needs and identify the right starting point.
Contact us
We’re here to help rare-disease innovators prepare effectively for EU JCA and patient-centred evidence needs.
EU JCA & HTA Regulation (HTAR)
Frequently Asked Questions
The JCA is an EU-level comparative clinical effectiveness assessment under Regulation (EU) 2021/2282. It runs in parallel to EMA review and provides a single evidence base for national HTA and reimbursement decisions.
As of October 2025, JCA applies to oncology and ATMP products. It will expand to orphan medicines in 2028 and all centrally authorised medicines in 2030.
JCA covers clinical effectiveness and safety. Cost-effectiveness, budget impact and reimbursement remain national. JCA creates a shared evidence base but does not replace national HTA.
PICO stands for Population, Intervention, Comparator and Outcomes. It defines the scope of a Joint Clinical Assessment. Understanding how PICOs are likely to be shaped and where expectations may differ across Member States is part of the upstream preparation RAREready supports. Formal PICO design and submission strategy remain with specialist HEOR partners.
Patients and clinical experts contribute during scoping and assessment, bringing disease insight and lived experience. The HTA Secretariat manages selection, conflict-of-interest checks and confidentiality.
A JSC gives sponsors early feedback from HTA bodies on comparators, outcomes, evidence plans and patient engagement strategies. For rare disease teams, understanding what a JSC is likely to surface — and preparing internal thinking accordingly is a useful part of upstream JCA readiness.
Orphan medicines enter mandatory JCA scope in 2028, but many sponsors are beginning to prepare now. Rare disease programmes involve particular complexity – small populations, single-arm trials and diverse comparators – which makes early upstream preparation especially valuable. RAREready is designed to support that preparation in a practical, lightweight way.
Yes. PED and validated PROs help show why outcomes matter to patients. Regulators and HTA bodies expect early and systematic patient input to support clinical benefit claims.
Experts are sourced through ERNs, EMA databases and patient networks. They sign COI and confidentiality agreements. Their input informs PICO scoping, evidence interpretation and assessment discussions.
The most useful preparation at this stage is internal – ensuring JCA thinking is visible when key asset decisions are being shaped, that ownership is clear across functions, and that EU and global perspectives are connecting effectively. RAREready supports teams in building exactly this kind of upstream readiness, before formal JCA timelines begin.
For rare disease programmes, the most useful window is now well before mandatory timelines begin in 2028. Once pivotal trial designs are locked and development decisions are made, the options available narrow significantly. Early upstream preparation avoids the need to respond reactively once the process is already in motion.
JCA readiness is genuinely cross-functional – it sits across Medical, HEOR, Regulatory, Market Access and Patient Engagement. One of the most common challenges teams are working through is how to define ownership clearly at asset level, so that JCA thinking is consistently applied rather than sitting between functions. This is a core part of what RAREready supports.
Early patient strategy reduces cost over time. Evidence gaps and late amendments are significantly more expensive to address once JCA timelines are in motion. Structuring patient insight early in a way that will hold up under joint assessment scrutiny strengthens the overall programme and reduces rework downstream.
Yes. EU guidance supports structured, transparent patient engagement. Using COI declarations, engagement frameworks and clear facilitation keeps collaborations compliant and credible.